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Cholesterol biosynthesis is integral to proper neurodevelopment due to the reliance on de
novo synthesis of cholesterol in the brain. Disruptions in this process have devastating outcomes
for human life characterized by several phenotypic manifestations concomitant with developmental
delay. The cholesterol biosynthesis disorder desmosterolosis is an extremely rare disorder with a
severe clinical phenotype, however, the models used to study this disease are not well characterized.
In addition to genetic disruptions in cholesterol biosynthesis, pharmacological perturbation is an
understudied side effect of many commonly prescribed drugs. Here we present a characterization
of the sterol profile of the mouse model of desmosterolosis followed by an examination of one such
pharmacological inhibitor of cholesterol biosynthesis, amiodarone. Amiodarone is a commonly
prescribed medication used to treat life-threatening atrial and ventricular arrhythmias with the
primary target being potassium channels and beta adrenergic receptors. We show that amiodarone
is also a potent inhibitor of several cholesterol biosynthesis enzymes in various cell culture models,
affecting the enzymes 24-dehydrocholesterol reductase (Dhcr24) and emopamil binding protein
(Ebp). Additionally we show that the serum of amiodarone users have elevated levels of
desmosterol, zymosterol, zymostenol and 8-dehydrocholesterol. Our study provides evidence that
the use of various medications, unrelated to cholesterol metabolism, may lead to potentially severe
clinical consequences related to the inhibition of sterol biosynthetic enzymes.
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CHAPTER 1: INTRODUCTION
Cholesterol biosynthesis
About 20-25% of cholesterol biosynthesis occurs in the liver, with additional synthesis
taking place in the brain, intestines, adrenal glands, and reproductive organs [1-4]. Cholesterol is
synthesized from acetyl-CoA through many, enzymatically processed intermediates (Figure 1) [5].
Cholesterol biosynthesis can be broken down into two major segments: pre-squalene and postsqualene cholesterol synthesis. Post-squalene synthesis converts lanosterol to cholesterol through
two major synthetic pathways: the Kandutsch-Russell pathway (favored in most tissues) and the
Bloch pathway. The Kandutsch-Russell pathway proceeds through a complex series of reactions
(lanosterol through zymostenol and lathosterol ending in 7-dehydrocholesterol (7-DHC)),
meanwhile the parallel Bloch pathway proceeds from lanosterol through zymosterol to desmosterol
[6]. The conversion of 7-DHC to cholesterol by DHCR7 and the conversion of desmosterol to
cholesterol by DHCR24 are the last steps in cholesterol biosynthesis [7, 8].

Cholesterol: an essential biomolecule for neurodevelopment
While the brain accounts for only 2% of total body weight in humans, it contains about
25% of all lipids. Cholesterol accounts for 20-30% of all lipids in the brain [6, 9, 10]. Cholesterol
metabolism in the brain differs markedly from that of other tissues due to the blood brain barrier
preventing cholesterol uptake from the circulation, thus the brain relies fully on de novo cholesterol
synthesis [11]. Importantly, cholesterol is synthesized by neurons: HMGCR and DHCR7, the first
and last enzymes in the cholesterol biosynthesis pathway, are strongly co-expressed at high levels
in neurons throughout the adult murine brain [12]. The function of cholesterol in the central nervous
system (CNS) goes beyond being a structural component of cellular membranes and lipid rafts: it
is required for synapse and dendrite formation, axonal guidance, and serves as a precursor for
various biosynthetic pathways [13]. Furthermore, it plays a critical role in the activity of the sonic
hedgehog pathway, an important signaling cascade that regulates morphogenesis in the brain [14].

Figure 1: Cholesterol biosynthesis scheme. A) Overview of de novo cholesterol biosynthesis. B) Detailed view of post-squalene cholesterol (red box in
(A)) biosynthesis with key steps and enzymes indicated.
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While endogenous cholesterol synthesis is essential for proper brain development, intact
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cholesterol metabolism is also critical for normal function of the adult brain: in the elderly, high
circulating cholesterol is associated with better memory function and conversely, low serum
cholesterol is associated with an increased risk for depression [15, 16]. Dysfunction of the
cholesterol biosynthesis pathways and/or metabolism leads and contributes to a number of
neurodevelopmental and neurodegenerative disorders such as Smith-Lemli-Opitz Syndrome
(SLOS) [17, 18], desmosterolosis [19-26], Niemann-Pick type C (NPC) disease [27], Huntington’s
disease [28-32], and Alzheimer’s disease [28, 32].

Cholesterol biosynthesis disorders
Defects in cholesterol biosynthesis present with severe abnormalities and developmental
disability [21, 22, 33-37]. In the post-lanosterol portion of the pathway there are several disorders
described, with the most prevalent being SLOS. Other disorders described in the literature include
lathosterolosis, X-linked dominant chondrodysplasia punctata 2 (CDPX2) and desmosterolosis.
With the exception of CDPX2, all sterol biosynthesis disorders discussed hereinafter follow an
autosomal recessive inheritance pattern. First we will discuss SLOS, the most common postlanosterol cholesterol biosynthesis disorder, followed by lathosterolosis, which presents with a very
similar clinical phenotype to SLOS, followed by CDPX2 and finally desmosterolosis, on which a
majority of the following work focuses on.
SLOS is caused by mutations in both copies in the gene encoding the last enzyme in the
cholesterol biosynthesis pathway – 7-dehydrocholesterol reductase (DHCR7) [38]. These can be
either identical (homozygous) or different on each allele (compound mutations) [39-41], one
inherited from each parent. It has a prevalence of ~1: 20,000 births, with males and females equally
affected [10, 42]. It is believed that heterozygous DHCR7 mutation carriers have >1% frequency
in the human population (9, 27, 32). To date, more than 165 DHCR7 missense mutations have been
identified, and when the two loss or reduced function mutant alleles combine, they result in SLOS
with varying degrees of clinical severity, depending on how much DHCR7 function is retained [41,
43]. Mutations that completely abolish cholesterol biosynthesis are incompatible with life,
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therefore only mutations that spare at least some cholesterol biosynthesis are observed. Mutations
in DHCR7 result in diminished cholesterol and desmosterol biosynthesis and accumulation of the
precursor 7-DHC in various tissues [17]. SLOS is characterized by multiple congenital
malformations and defects, photosensitivity, impaired cognitive function, and behaviors of autism
spectrum disorder (ASD) [44, 45].
Lathosterolosis was first described in 2002 in an infant presenting with severe congenital
microcephaly, hexadactyly of the left foot, syndactyly of multiple toes and liver dysfunction
detected in the first year of life. During the first two years, severe psychomotor delays became
apparent, with the deficits closely resembling the SLOS phenotype. However, biochemical analysis
revealed a lack of 7-DHC accumulation which is the biochemical hallmark of SLOS. Instead, this
patient had greatly elevated levels of lathosterol and upon further investigation it was revealed that
fibroblasts from this patient had impaired SC5D activity. To date, there have been only 5 cases of
lathosterolosis reported in humans, with the most recent case being very mild and diagnosed much
later in life than the four previous cases [46]. Due to the phenotypic overlap of SLOS and
lathosterolosis the first four reported cases of lathosterolosis required exclusion of SLOS by way
of sterol profiling to arrive at the diagnosis of lathosterolosis.
CDPX2 arises from mutations in the emopamil binding protein (EBP) gene which encodes
for the cholesterol biosynthetic enzyme sterol-delta(8)-isomerase. CDPX2 patients present with
skin defects as well as skeletal abnormalities including short stature and craniofacial defects [47].
Biochemically, patients present with elevated levels of 8-dehydrocholesterol (8-DHC) and
zymostenol [48]. The ‘Tattered’ mouse model contains a semi-dominant mutation in the Ebp gene
that is prenatally lethal for males while females survive but are smaller in stature and have coat
striping similar to the skin phenotype of heterozygous human females with CDPX2. The striping
of the mouse coat and the analogous skin defects in humans such as whorled atrophic and
pigmentary lesions, striated hyperkeratosis, coarse lusterless hair and alopecia as well as the
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craniofacial defects present in both Tattered mice and humans have been linked to alterations in
the function of EBP. Due to the X-linked nature of the disease, very few cases have been reported
in males as CDPX2 is typically lethal in males which is recapitulated in the Tattered mice [49].
One report of a male with CDPX2 attributed survival to his 47,XXY karyotype, while other reports
of males with CDPX2 attribute survival to hypomoprhic mutations or single gene mosaicism [5052]. The characteristic features of epiphyseal and periepiphyseal stippling, asymmetries, patchy
alopecia of the scalp, brow, and lashes, linear arrays of hypotrophic changes of the skin, structural
vertebral anomalies and scoliosis, characteristic facial features, polydactyly and small stature have
been observed in both female and male patients with CDPX2, though not all features are present in
every patient.

Desmosterolosis
Desmosterolosis is a rare autosomal recessive disorder caused by mutations in the Dhcr24
gene that encodes the enzyme 24-dehydrocholesterol reductase. Homozygous or heterozygous
Dhcr24 mutations result in systemic elevation of desmosterol and decreased levels of total
cholesterol [20, 22, 26]. The Dhcr24 gene is mapped to chromosome 1p33-p31.1 and eight
missense mutations have been described in the coding region of 1550 bp (NM_014762.3) to date.
Observed clinical findings of desmosterolosis include shortening and flexion of extremities, brain
malformations such as hydrocephalus, absent septum pellucidum and thin corpus callosum,
dysmorphic facial features, syndactyly, developmental delay and diaphragmatic eventration [2022, 24-26].
Desmosterolosis and SLOS have overlapping clinical findings and mouse models of both
disorders lead to early postnatal death [19]. It seems that the accumulation of desmosterol is more
detrimental than the accumulation of 7-DHC, as DHCR24 mutations in humans are most often
incompatible with life – there are only 10 reported cases of desmosterolosis in the literature since
the first report in 1998 [23]. The number of reported cases of desmosterolosis is likely to increase
as diagnostic tools available to clinicians advance and genetic sequencing of newborns becomes
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more common. Given our experience in characterizing the SLOS mouse model, we decided to
undertake the characterization of the mouse model of desmosterolosis as well. The analysis of the
desmosterolosis model and comparison to the SLOS model help to illustrate the importance of
desmosterol and 7-DHC in neuronal development in addition to the consequences lack of
cholesterol has on this process.

History of desmosterolosis mouse models
The original Dhcr24 knockout mice (C57BL/6x129SvEv) were described by the laboratory
of Dr. Elena Feinstein (mice were generated through service agreement with Lexicon Genetics
Incorporated). The targeting vector had a 249 bp deletion in Dhcr24 exon 1 and was electroporated
into 129/SvEvBrd (Lex-1) ES cells. The ES cell clones were microinjected into C57BL/6 albino
blastocysts and the resulting chimeras were mated to C57BL/6 (albino) females to generate mice
heterozygous for the Dhcr24 mutation. There are three articles published by the senior team of Drs.
E. Feinstein and I. Bjorkhem. The first report is in Science 2003 [53], the second in JBC 2006 [54]
and the third in Arterioscler Thromb Vasc Biol 2007 [55]. The Science 2003 is a one-page report,
with one figure and two supplemental figures showing that Dhcr24-KO mice are viable and survive
[53]. The JBC 2006 manuscript used these same mice and analyzed CYP46A1 transcriptional
regulation [54]. In Figure 2A of the 2006 JBC manuscript there is a graph showing brain cholesterol
and desmosterol concentration in WT and Dhcr24-KO mice but these data were recalculated from
the Science 2003 article. The ATVB 2007 manuscript [55] studies the same mouse model by the
same investigators, comparing Dhcr24-KO mice with Dhcr24-Het mice however, there is no data
presented for WT mice. The focus of study was the hepatic sterol homeostasis which included the
analysis of hepatic mRNA levels for sterol related genes, bile acids quantification and
measurements of plasma oxysterols [55].
In the meantime, the original Dhcr24 knockout mice were made available to other
investigators who initiated backcrossing of Dhcr24-KO mice to C57BL/6J background. In addition
to the initial three reports [53-55], there were four more publications from the Seo group [56-59]
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and one publication by Kuehnle et al. [60] using Dhcr24-KO mice. The Seo group (Nagoya
University, Japan) obtained mice from Quark Biotech Inc. (Fremont, CA) and backcrossed with
C57BL/6J for more than five generations and described the phenotype [58] that is identical to
phenotype described in the current study. Three publications by this group focused on skin changes
in Dhcr24-KO mice [57-59] and one was focused on mouse embryonic fibroblasts isolated from
Dhcr24-KO mice [56]. Kuehnle et al. obtained mice from Quark [60] performing experiments in
SH-SY5Y cells and in primary neuronal cultures from WT and Dhcr24-KO brains, but provided
no details on the mouse phenotype. This group cultured primary neurons in presence of serum and
cholesterol. Based on our experience with primary neuronal cultures (and various cellular models
of SLOS), the phenotype (elevated desmosterol) does not manifest in the presence of serum and
cholesterol. Thus, we grow cortical neurons in serum-free defined medium without cholesterol
supplementation as described in Chapter 2: Primary neuronal cultures.
Information

available

from

the

Jackson

Laboratory

website

(https://www.jax.org/strain/012564; under the tab Details>Development) states the following:
“This same mouse model developed by Dr. Feinstein’s group was sent to Dr. Shailenra B. Patel
(while at Medical University of South Carolina) where they were backcrossed to C57BL/6J mice
for three generations. Dr. Patel moved his colony to Medical College of Wisconsin, and then further
backcrossed the colony to C57BL/6J mice for 11 more generations. Heterozygous mice
backcrossed to C57BL/6J for total of at least 14 generations were sent to The Jackson Laboratory
Repository. Upon arrival, mice were bred to C57BL/6J (Stock No. 000664) for at least one
generation to establish the colony.” We purchased these mice from the Jackson Laboratory.
Compared to the original Science 2003 [53] report that Dhcr24-KO mice are viable, these
same mice on C57BL/6J background are neonatal lethal. The Dhcr24-KO phenotype (reduced
number of Dhcr24-KO pups at birth; if born, lethal shortly after birth; wrinkle-free skin) has been
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reproduced by the investigators in Japan and now by us. While Seo’s group focused on the role of
Dhcr24 in the skin, we present data relevant to central nervous system development.

Pharmacological inhibition of Dhcr7 and Dhcr24
While essential for life as an integral part of membranes and indispensable for the nervous
system, cholesterol has a bad reputation as the culprit in hypertension and cardiovascular diseases
[61]. Therefore over the last seven decades pharmaceutical companies have worked to develop
compounds to inhibit cholesterol synthesis. Initial efforts focused on the inhibition of the last two
enzymes in the pathway, Dhcr7 and Dhcr24. In 1960 the drug triparanol (BIBX79, NB-598, MER29) was introduced in the US as the first synthetic cholesterol-lowering drug. However, due to
severe adverse effects the drug was withdrawn in 1962 [62]. Triparanol decreased cholesterol levels
by inhibiting Dhcr24 while simultaneously elevating desmosterol levels.
Another sterol synthesis inhibitor, AY9944, was found to be teratogenic [63] before
entering into clinical trials. This compound is an inhibitor of Dhcr7 and is currently used to induce
a pharmacological model of Smith-Lemli-Opitz syndrome in rats [64]. Pregnant rats are injected
with AY9944 and the injections continue in newborn pups until they reach 3 months of age.
AY9944 is very toxic, so much so that very low concentrations of the drug have to be injected to
prevent lethal phenotype. The AY9944-treated rats have biochemical profiles characteristic for
SLOS and develop retinal degeneration [65].
Another example of chemical inhibition of Dhcr7 with negative consequences is the use of
the frequently prescribed antipsychotic, aripiprazole. Cell culture studies have shown that
aripiprazole inhibits the Dhcr7 enzyme [66-68]. Analysis of samples from patients taking
aripiprazole showed that 7-DHC is significantly elevated in their blood [69]. Studies in our
laboratory have shown that, when given to pregnant mice, aripiprazole increases 7-DHC in progeny
in both tissue and serum. This biochemical change, greatly elevated 7-DHC, is a characteristic
finding present in tissues and serum of the mouse model of SLOS [70]. Aripiprazole is not currently
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contraindicated for use during pregnancy but rather the American College of Obstetricians and
Gynecologists recommends individualized therapy during pregnancy [71]. A review of literature
on the use of pharmaceutical inhibitors showed that the inhibitors of Dhcr7 are teratogenic [43].
These examples illustrate the unintended consequences and side effects of various medications
currently in use. While beneficial to patients with psychiatric disorders, a special caution should be
taken when aripiprazole is prescribed to pregnant women.
In an effort to identify other pharmaceutical and experimental drugs that have off-target
effects on cholesterol biosynthesis, our laboratory performed a series high-throughput screenings
over the last several years. In total, we have profiled the effects of about 3,000 compounds on
cholesterol biosynthesis in various cell culture models [66-68]. These studies concluded that 5 to
10% of all compounds interfere with one of the enzymatic steps in post-lanosterol biosynthesis
pathway. Considering that there are eight known genetic diseases caused by the mutations in sterol
enzymes [72], it is alarming evidence that the use of various medications not intended to affect
cholesterol metabolism, may lead to potentially severe clinical consequences related to the
inhibition of sterol biosynthetic enzymes.
Amiodarone is commonly used to treat a variety of cardiovascular conditions and it was
recognized that it might affect total cholesterol levels [73, 74]. However, only very recently it was
reported that the users of amiodarone have greatly elevated desmosterol levels in their serum [75].
Interestingly, amiodarone’s structure is strikingly similar to that of triparanol, with both containing
a triethylamine moiety with an ether linkage to the rest of the compound (Figure 2). Of potential
concern is one clinical case report about a child with developmental disabilities. After thorough
exclusion of genetic causes, the only plausible identified cause was the use of amiodarone by
mother during the pregnancy [76]. Thus, we designed the experiments to test the effects of
amiodarone on cholesterol biosynthesis in a neuronal cell line, Neuro2a and in primary cultures of
mouse neurons and astrocytes.
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Effects of amiodarone on
cholesterol biosynthesis
Amiodarone
commonly

is

prescribed

a
anti-

arrhythmic drug predominantly
used

in

ventricular

the

treatment

arrhythmias

of
[77].

Additionally it is also used to treat
other cardiovascular conditions
including atrial fibrillation, atrial
flutter, refractory atrioventricular
nodal and atrioventricular reentrant tachycardia. The primary
action of amiodarone is blocking
potassium rectifier currents in the
heart [78]. Other actions of

Figure 2: Chemical structure of amiodarone (CAS 1951-25-3)
and triparanol (metasqualene; CAS 78-41-1).

amiodarone include effects on beta-adrenergic receptors, calcium and sodium channels.
Amiodarone was the 198th most prescribed medication in the US in 2016 with 2.9 million
prescriptions [79] and is on the World Health Organization list of essential medicines [80].
The starting dose for amiodarone is 800-1600 mg per day taken orally in a single dose for
1-3 weeks. The dosage is then decreased to 100-200 mg per day in a single dose for maintenance
[81]. It is important to consider that the drug has a very long elimination half-life at 58 days on
average [82], while its active metabolite mono-N-desethylamiodarone (MDEA) has a 36 day halflife, though it may not reach steady state levels for up to a year [83]. Both amiodarone and MDEA
accumulate in adipose tissue as well as the liver and lungs. Due to the long half-life and this
accumulation in multiple tissues, the adverse effects of amiodarone may take several months to
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relent upon cessation of the drug. In fact, the major risk factor for clinically significant toxic side
effects identified by a retrospective study of amiodarone users’ medical records was duration of
treatment, with 1.6-2.8% of users being affected [84].
The most commonly listed side effect of amiodarone use is corneal microdeposits which
occur in most users, followed by cardiac, pulmonary and liver toxicity as well as hypo- and hyperthyroidism. Dermatologic effects such as blue skin discoloration and photosensitivity have also
been reported [77]. Neurologic toxicity symptoms range from cognitive impairment to peripheral
neuropathy, ataxia and in rare cases, quadriplegia. We were interested to determine if the
neurological toxicity might be related to the ability of amiodarone to alter cholesterol synthesis.
Recent studies showed that the most affected pathway in rats treated with amiodarone was
cholesterol biosynthesis [73, 74, 85]. This is an interesting observation considering the importance
of cholesterol for maintaining membrane fluidity and composition. Both of these aspects may then
affect the functioning of potassium channels and other membrane proteins [86]. Amiodarone is
capable of crossing the blood brain barrier and due to the brain’s reliance on de novo cholesterol
biosynthesis, perturbation of this process by prescription drugs is necessary to consider when
attempting to understand the etiology of off-target effects. Since the mechanism by which
amiodarone alters cholesterol biosynthesis is unknown, further analysis of amiodarone’s effects on
cholesterol synthesis may help to elucidate this mechanism. Here we show the effects of
amiodarone on neuronal and glial sterol synthesis and examine the sterol composition in serum of
amiodarone users.
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CHAPTER 2: METHODS
Mouse studies
Adult mice, B6.129S5-Dhcr24tm1lex/SbpaJ, stock no: 012564 and B6.129P2(Cg)-Dhcr7tm1Gst/J,
stock no: 007453 were purchased from the Jackson Laboratory. The mice were housed under a 12hr light-dark cycle at constant temperature (25 °C) and humidity with ad libitum access to food and
water in Comparative Medicine at UNMC, Omaha, NE. Embryonic and newborn mice from Het
(Dhcr24+/-) x Het (Dhcr24+/-) and Het (Dhcr7+/-) x Het (Dhcr7+/-) matings were used for the study.
The whole brain was dissected then bisected along the longitudinal fissure prior to freezing in 2methyl butane pre-chilled on dry ice and stored at -80°C. Tail clips were collected for genotype
confirmation. Half of the brain was used for sterol analysis and the other half was used for either
total RNA extraction and qPCR or protein extraction and western blotting. All procedures were
performed in accordance with the Guide for the Humane Use and Care of Laboratory Animals. The
use of mice in this study was approved by the Institutional Animal Care and Use Committee of
UNMC.

Study population
Serum samples were obtained from the Nebraska Biobank, a repository comprised of
residual samples from patients who consent to donate any blood, serum or plasma left-over after
laboratory testing. The Nebraska Biobank serves UNMC faculty as part of the Center for Clinical
and Translational Research. The Biobank contains de-identified serum, plasma, and genomic DNA
from consented patients’ residual clinical laboratory samples. De-identified data is available for all
samples and includes demographics, encounters, diagnoses, problem list, medications, procedures
(including labs), and OB/GYN data. The Nebraska Biobank functions as a fee for service core
facility at UNMC and is available to all NU System faculty at a subsidized rate. Electronic Health
Record personnel identified a group of samples from users of amiodarone and an age and sex
matched control group. The use of Biobank de-identified samples is not subject to regulations and
as such does not require review and approval by the IRB.
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Primary neuronal cultures
Primary cortical neuronal cultures were prepared from WT E15 mice. Pregnant females
were anesthetized by isoflurane and sacrificed by decapitation. Embryos were dissected out and
sacrificed by decapitation immediately after removal from the uterus. The brain was placed in prechilled HBSS solution (w/o Ca2+, w/o Mg2+) and cerebral cortices were dissected, meninges
removed and cut into small chunks of similar sizes and transferred to Trypsin/EDTA (0.5%) (VWR
International) for 25 min at 37°C. Following the incubation, trypsin solution was replaced with
trypsin inhibitor (Sigma) solution and the tissue was centrifuged for 5 minutes. Tissue pieces were
resuspended in Neurobasal medium with B-27 (Thermo Fisher Scientific) supplement and
triturated with a fire-polished Pasteur pipette. The cells were pelleted by centrifugation for 5 min
at 80 X g. The cell pellet was resuspended in Neurobasal medium with B-27 supplement and the
cells were counted. The cells were plated on a poly-D-lysine coated 96-well plate at density 50,000
cells/well. The growth medium was Neurobasal medium plus B-27 supplement plus Glutamax
(Thermo Fisher Scientific) plus 3 μM cytosine arabinoside. Incubation was in the cell culture
incubator (37°C, 5% CO2) for 3 – 6 days. At the end of incubation, the cultures were processed for
immunocytochemistry.

Primary astrocytic cultures
After plating the required number of cells for neuronal cultures, left-over cells were plated
in 100 mm dishes at density of 10x106 per tissue culture plate in DMEM with 10% FBS. Under
these conditions, astrocytes adhere and divide and completely populate the plate within 10-14 days.
Once the plates were full, they were rinsed using the cold jet method [87], briefly 4°C media was
pipetted over the cells to detach non-astrocytic cells, leaving only adherent astrocytes. The
astrocytes were trypsinized and plated in 96-well plates in DMEM plus 10% FBS at 30,000
cells/well. The following day the medium was completely changed and astrocytes were grown in
Neurobasal medium with B-27 supplement in the absence of cholesterol (same medium as neuronal
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cells without cytosine arabinoside). Cells were incubated at 37°C, 5% CO2 for 6 days. At the
endpoint of incubation, cells were counted as described in a later section.

Control Neuro2a and Ebp-deficient Neuro2a cultures
The neuroblastoma cell line, Neuro2a, was purchased from ATCC (Rockville, MD). EPBdeficient Neuro2a cells were generated by Ebp shRNA (Open Biosystems) transfection. A stable
cell line expressing Ebp shRNA was established using puromycin selection. The controls for Ebpdeficient Neuro2a cells were Neuro2a cells transfected with non-silencing shRNA and Neuro2a
transfected with an empty plasmid. The cell lines were maintained in EMEM supplemented with
L-glutamine, 10% FBS, and penicillin/streptomycin at 37°C and 5% CO2 (plus puromycin for Ebpdeficient Neuro2a cells, non-silencing Neuro2a and empty plasmid Neuro2a). Cells were
subcultured once a week and the culture medium changed every 2 days. For experimental purposes,
the cells were plated in either 100 mm plates (protein extraction and RNA isolation), or 96-well
plates (for sterol analysis and immunocytochemistry). To assess the endogenous sterol synthesis,
these cultures were grown in defined medium without cholesterol and without lipids by using
EMEM with N2 supplement, L-glutamine, and penicillin/streptomycin (plus/minus puromycin). At
specific times, the cells were harvested from 100mm plates by removing medium, washing once
with 5 mL 1X PBS, and then scraping cells with a spatula in 5mL 1X PBS. Cells were centrifuged
for 8 min at 700 rpm at 4˚C and PBS was removed before RNA isolation or protein extraction.

Immunocytochemistry and imaging
Neurite outgrowth of E15 neuronal cultures was evaluated on an ImageXpress Pico
Automated Cell Imaging System using a 20X Fluotar objective in the Cy3 channel. Images were
acquired and analyzed with CellReporterXpress software (Molecular Devices). For each well 49
individual fields were captured and stitched together. The neurite growth was analyzed by the
neurite tracing algorithm in CellReporterXpress.

15

RNA isolation and clean-up
Brains were dissected from P0 pups and homogenized in 1 mL of ice cold TRIzol Reagent
(Thermo Fisher Scientific). RNA was isolated following the protocol included with the TRIzol
Reagent. RNA pellets were redissolved in nuclease-free water. RNA concentration and quality
were measured using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific). 100 µg of
isolated RNA was then cleaned using Qiagen’s RNeasy Mini Kit following the manufacturer’s
protocol, including the on-column DNase digestion. RNA quality and quantity were measured
again following the cleanup protocol.

Complementary DNA synthesis and RT2 Profiler PCR Mouse Arrays
500 ng of total RNA was reverse transcribed using the First Strand cDNA Synthesis Kit
(Qiagen) following the manufacturer’s protocol. PCR data were collected by the StepOne Software
v2.3 (Thermo Fisher Scientific) and analyzed by Qiagen’s PCR Array Data Analysis Web Portal.
Several methods to normalize gene expression changes were used, including the best fit from the
panel of housekeeping genes and geometric mean from the full plate. Only gene expression changes
that were statistically significant with all normalization protocols are presented in the Chapter 3.

Western blotting
Whole brain samples of Dhcr24+/+, Dhcr24–/– and Dhcr24+/- newborn mice were
homogenized by sonication in ice-cold RIPA lysis buffer (VWR International) plus phosphatase
inhibitors (Sigma-Aldrich) and protease inhibitors (Thermo Fisher Scientific) and incubated on ice
for 30 min. To clear the lysates, the samples were spun at 14,000 X g at 4°C for 5 min to pellet the
debris. The protein concentration of the supernatant was quantified by PierceTM BCA Assay
(Thermo Fisher Scientific). Equal amounts of protein from each sample were mixed with reducing
reagent and loading buffer and heated to 70°C for 10 min. Proteins were separated on NuPAGE™
4-12% Bis-Tris Protein Gels (Thermo Fisher Scientific). Pre-stained protein was used to evaluate
the molecular weight. The Bio-Rad Mini Trans-Blot Electrophoretic Transfer Cell was used for the
electrophoretic transfer using polyvinylidene difluoride membranes (Immobilon-P PVDF
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Membrane, Sigma-Aldrich) and transfer buffer (25 mM Tris, 192 mM glycine and 20% (v/v)
methanol (pH 8.3)). Following transfer, PVDF membranes were blocked in 5% milk in TBS (50
mM Tris-Cl, 150 mM NaCl, pH 7.5) with 0.05% Igepal (Spectrum Chemical) and incubated in
primary antibody overnight at +4°C and secondary antibodies at room temperature for 1 hour.
Membranes were probed with the following primary antibodies: anti-DHCR24 (Cell Signaling),
anti-beta-actin (Cell Signaling), anti-GAPDH (Cell Signaling) and anti-MAP2 (Cell Signaling).
Western blots were developed using Azure’s Radiance Substrate, imaged on an Azure C300 with
the cSeries Capture Software and saved as TIFF images (Azure Biosystems). The TIFF images
were analyzed with AzureSpot and data graphed in GraphPad Prism 8 (GraphPad Software).

Cell counting
Cells were counted on an ImageXpress Pico Automated Cell Imaging System at 4X Fluotar
objective in the DAPI channel. To stain the nucleus, 100 µL of a 1:2000 dilution of Hoechst dye
(Thermo Fisher Scientific) in PBS was added to each well and incubated for 5 minutes before data
acquisition. Cells were counted using the cell counting algorithm in CellReporterXpress.

Sterol extraction for HPLC-MS/MS analysis
Tissue
Brains were homogenized in ice-cold 1X PBS using a Q55 sonicator (Qsonica). To a 5 µL
aliquot of homogenate, Folch’s solution (600 µL; 2/1 chloroform/methanol), aqueous NaCl
solution (0.9%, 300 µL) and 10 µL of an internal standard mix (30 µM D7-cholesterol, D7-7-DHC,
D7-8-DHC, 13C3-desmosterol and 13C3-lanosterol) were added. The samples were then vortexed for
1 min and centrifuged at 10,000 RCF for 10 min. The bottom organic phase was collected and dried
in a Savant Integrated SpeedVac® System (Thermo Fisher Scientific) and then redissolved in 100
µL of MeOH and transferred to a mass spec compatible plate pre-deposited with 200 µg 4-Phenyl1,2,4-triazoline-3,5-dione (PTAD) per well and sealed with Easy Pierce Heat Sealing Foil (Thermo
Fisher Scientific). Values were normalized to total protein as quantified by Pierce™ BCA assay
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(Thermo Fisher Scientific) reading absorbance at 562 nm using a Spectromax Plus 384 (Molecular
Devices) and reported as nmol/mg protein.
Serum
To a 10 µL aliquot of human serum, Folch’s solution (600 µL; 2/1 chloroform/methanol),
aqueous NaCl solution (0.9%, 300 µL) and 10 µL of an internal standard mix (30 µM D7cholesterol, D7-7-DHC, D7-8-DHC, 13C3-desmosterol and 13C3-lanosterol) were added. The samples
were then processed as the tissue samples described above. Values were normalized to volume and
reported as ng/µL serum.
Cell cultures
Sterol levels were analyzed in individual wells and, for most experiments, cellular levels
correspond to 8-12 technical replicates. After removing the medium, 200 μL of MeOH containing
internal standard (30 µM D7-cholesterol, D7-7-DHC, D7-8-DHC,
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C3-desmosterol and
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C3-

lanosterol) were added. The 96-well plates were placed on an orbital shaker for 30 min at room
temperature. An aliquot (100 µL) of the supernatant was transferred to a PTAD-predeposited plate,
sealed with Easy Pierce Heat Sealing Foil followed by 30 min agitation at room temperature and
analyzed by LC-MS/MS. Values were normalized by cell count per well and reported as
nmol/million cells.

HPLC-MS/MS (SRM) analyses of sterols
The samples were placed on an Acquity UPLC system coupled to a Thermo Scientific TSQ
Quantis mass spectrometer equipped with an APCI source. Then 5 μL was injected onto the column
(Acquity BEH C18 1.7 μm, 2.1 mm × 50 mm ) with 100% MeOH (0.1% v/v acetic acid) mobile
phase for 1.0 min runtime at a flow rate of 500 μL/min. Natural sterols were analyzed by selective
reaction monitoring (SRM) using the following m/z transitions: cholesterol 369 → 369, 7-DHC 560
→ 365, 8-DHC 558 → 363, desmosterol 592 → 560, lanosterol 634 → 602, with retention times
of 0.7, 0.4, 0.4, 0.3 and 0.3 min, respectively. SRMs for the internal standards were set to: d7-Chol
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376 → 376, d7-7-DHC 567 → 372, d7-8-DHC 565 → 370,

C-desmosterol 595 → 563,

13

13

C-

lanosterol 637 → 605.

Sterol extraction for GC-MS analysis of sterols
Serum
To a 10 µL aliquot of human serum, Folch’s solution (600 µL; 2/1 chloroform/methanol),
aqueous NaCl solution (0.9%, 300 µL) and 10 µL of an internal standard mix (30 µM D7cholesterol, D7-7-DHC, D7-8-DHC) were added. The samples were then vortexed for 1 min and
centrifuged at 10,000 RCF for 10 min. The bottom organic phase was collected in a glass
autosampler vial and dried in a Savant Integrated SpeedVac® System (Thermo Fisher Scientific).
Dried lipid samples were derivatized with 35 µL N,O-bis(trimethylsilyl)trifluoroacetamide
(BSTFA) and transferred to a glass autosampler vial insert for analysis. Values were normalized
by volume of serum and reported as ng/µL of serum.
Cell cultures
Single wells were extracted with 200 μL of MeOH containing an internal standard cocktail
(30 µM D7-cholesterol, D7-7-DHC, D7-8-DHC). An aliquot (190 µL) of the supernatant was
transferred to glass autosampler vial. Three adjacent wells were combined in each vial before
drying. Samples were dried in a SpeedVac concentrator. Dried lipid samples were derivatized with
BSTFA and transferred to a glass autosampler vial insert for analysis. Values were normalized by
average cell count and reported as fold change over control (DMSO for amiodarone, non-silencing
shRNA for Ebp-deficient Neuro2a).

GC-MS analysis of sterols
5 μL of BSTFA-derivatized lipid sample was injected onto the column (SPB-5, 0.25 μm,
0.32 mm × 30 m) with the following temperature program: 180°C was held for 1 min; then
increased to 250 °C at 20°C/min; then raised to 300°C at 4°C/min and kept for 7 min. Selected
sterol intermediates were analyzed by extracted ion chromatogram (EIC) using the following
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values: cholesterol (m/z 458, retention time 16.9 min), zymostenol (m/z 458, retention time 17.1
min), zymosterol (m/z 456, retention time 17.4 min) and D7-Chol (m/z 465, retention time 16.9
min). Final sterol numbers were calculated using D7-Chol as the internal standard. Response factors
were calculated for each sterol and used to calculate the total amount.

Serum drug extraction
To 75 µL of human serum were added 188 µL H2O, 10 µL internal standard (d8aripiprazole) and 75 µL of 4.5 M ammonium hydroxide. The samples were then vortexed
vigorously for 1 minute. Following vortexing, 950 µL of methyl tert-butyl ether (MTBE) was added
to each sample followed by another minute of vortexing. Samples were then centrifuged at 10,000
RCF for 10 minutes. The top organic layer was collected to a glass autosampler vial and dried in a
SpeedVac. After samples were dried 150 µL of MeOH/NH3•H2O (95:5, v/v) was added to each
vial, briefly vortexed and then transferred to a chromatography vial insert for LC-MS/MS analysis.

Serum drug measurements
Amiodarone and MDEA levels were acquired on an Acquity UPLC system coupled to a
Thermo Scientific TSQ Quantis mass spectrometer using an ESI source in the positive ion mode.
5 μL of each sample was injected onto the column (Phenomenex Luna Omega C18, 1.6 μm, 100
Å, 2.1 mm × 50 mm) using water (0.1% v/v acetic acid) (solvent A) and acetonitrile (0.1% v/v
acetic acid) (solvent B) as mobile phase. The gradient was: 10% to 40% B for 0.5 min; 40% to
95% B for 0.4 min; 95% B for 1.5 min; 95% to 10% B for 0.1 min; 10% B for 0.5 min.
Amiodarone and MDEA levels were analyzed by selective reaction monitoring (SRM) using the
following m/z transitions: amiodarone 646 → 86, and MDEA 618 → 72. The SRM for the internal
standard (d8-aripiprazole) was set to 456 → 293 and response factors were determined to accurately
determine the drug levels. Final drug levels are reported as ng/mL of serum.

Statistical analyses
Data are presented as the mean ± standard error of the mean. Unpaired two-tailed t-tests
were performed for individual comparisons between two groups, employing Welch’s correction
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when the variances between the two groups were significantly different. A one-way ANOVA with
multiple comparisons and Tukey corrections were performed for comparisons between three or
more groups. The P values for statistically significant differences are highlighted in Figure
Legends. Statistical analyses were performed using GraphPad Prism version 8 (GraphPad
Software) for Windows and Microsoft Excel 2016.
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CHAPTER 3: RESULTS
Cholesterol, desmosterol and 7-DHC levels show a developmental trajectory
Cholesterol is the major sterol in brain tissue and starts accumulating early in embryonic
development. However, the temporal production of cholesterol and its two immediate precursors
(desmosterol and 7-DHC) in the brain is not well understood to date. To gain insight into this
process, we compared the levels of cholesterol and its immediate precursors starting from
embryonic stages (E9) to adulthood (P240) in the brain (Figure 3).
We found that compared to cholesterol, the absolute levels of its precursors were
significantly lower at all stages of development: cholesterol was an order of magnitude more
abundant than desmosterol, while desmosterol was an order of magnitude higher than 7-DHC.
Cholesterol, desmosterol and 7-DHC each had a distinct developmental trajectory. The most
significant increase in cholesterol levels was observed from E17 to P30, with levels plateauing
thereafter. Desmosterol levels increased linearly from E9 through P0 and after P30 stayed at low
levels. In contrast, 7-DHC was present at very low levels in the mouse brains, peaking at P7 and
declining thereafter.
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Figure 3: Ontogeny of cholesterol, desmosterol and 7-DHC in the mouse brain from E9 to P240.
Note the different y-axis for all three sterols. Embryonic stages E13-15 and E16-18 were combined and
labeled E14 and E17 respectively. n values for each time point: E9 = 3; E14 = 13; E17 = 8; P0 = 23; P30
= 3; P60 = 3; P150 = 3 and P240 = 2.
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Cholesterol deficiency leads to early postnatal death
Desmosterolosis is an autosomal recessive disorder with Mendelian inheritance, thus the
expected frequency of knockouts is approximately 25%. In our mouse colony we found a slightly
lower than expected number of Dhcr24-KO mice (Figure 4A): in 12 litters with total 96 embryos
(average number of embryos per litter = 8) we obtained 21% of KOs. At P0, Dhcr24-KO pups
could be visually identified by lack of wrinkled skin, shorter limbs and a missing a milk spot
(Figure 4B). Western blot
analyses of P0 brains revealed
DHCR24

protein

was

completely absent in Dhcr24KO pups, while Dhcr24-Het
mice brains revealed a 50%
reduction of DHCR24 when
compared to WT littermates
(Figure 4C). At P0, in
addition

to

commonly

observed KO stillborn pups (9
stillborn out of 27 born), all
live-born

KO

shortly

pups

after

Furthermore,

died
birth.

KO

pups

weighed approximately 10%
less than WT littermates (P <
0.0001),

while

WT

and

Dhcr24-Het P0 weights were
comparable (Figure 4D).

Figure 4: Knockout of Dhcr24 affects viability and birth weight of
mice. A) Number of embryos by genotype, E9-E18, recovered from 12
litters. B) An example of a litter with 3 KO pups (indicated by stars).
The KO pups lack milk spots, have shorter legs and necks and wrinklefree skin. C) DHCR24 protein expression is absent in Dhcr24-KO
brains and is greatly decreased in Dhcr24-Het brains. D) Number of P0
pups obtained from 12 litters that contained pups of all three genotypes.
P0 KO pups are significantly lighter than their WT or Het littermates.
**** P < 0.0001.
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Desmosterol is greatly elevated in the brains of Dhcr24-deficient mice
Next, we compared cholesterol, desmosterol and 7-DHC levels in brains of WT, Het and
Dhcr24-KO littermates during embryonic development and shortly after birth (Figure 5). While
there was a steady increase of cholesterol and desmosterol in the WT and Het brains during
embryonic stages, no accumulation of cholesterol in Dhcr24-KOs could be observed. Instead,
desmosterol steadily accumulated in embryonic KO brains, reaching comparable levels to that of
cholesterol seen in the WT brains by P0. Interestingly, the difference among WT, Het and Dhcr24KO sterol levels was already present at E14, with the most pronounced differences at P0. Our results
also confirmed previously reported data that endogenous brain cholesterol synthesis in the
developing brain starts around E12 [88, 89].
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Figure 5: Desmosterol is greatly elevated in the brains of Dhcr24-deficient mice. A) Comparison of
cholesterol, desmosterol and 7-DHC levels in mouse brains during development. WT are shown in gray,
Het in blue and KO in red. B) Statistical significance values for (A). C) n values for all groups in (A). *P
< 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Desmosterol is elevated in Dhcr24-Het mice compared to WT littermates
Since we found that desmosterol is significantly elevated in P0 brain of Dhcr24-Het mice,
we hypothesized that in these mice i) elevated desmosterol levels will persist into adulthood, and
ii) maternal Het genotype will by itself have an effect on the developing pups. The effect of the
maternal genotype on the pup’s brain sterol levels is shown in Figure 6. We found decreased
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cholesterol (P < 0.001) and increased desmosterol (P < 0.01) levels in the brain tissue of Dhcr24Het pups, which was independent of the maternal genotype (e.g. Dhcr24-Het pups originating from
Dhcr24-Het vs WT mothers). In addition, we observed that 7-DHC levels were elevated in Het
pups compared to their WT littermates in litters from Het mothers only (P = 0.0280). However, at
present, the biological significance of such a small elevation in 7-DHC is unclear.
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Figure 6: Cholesterol and desmosterol levels are not affected by maternal genotype. Sterols were
analyzed in the brains from WT and Dhcr24-Het pups derived from either WT or Dhcr24-Het mothers at
P0. The maternal genotype did not have an effect on the cholesterol and desmosterol levels in the brain of
newborn pups. n for maternal WT genotype: 16 WT pups and 14 Het pups; n for Het maternal genotype:
8 WT pups and 18 Het pups. *P < 0.05; ***P < 0.001; ****P < 0.0001.

Next, desmosterol, 7-DHC and cholesterol levels were compared across different brain
regions and the whole brain of two-month-old WT and Dhcr24-Het mice. While there was a
significant difference in cholesterol levels between WT and Het brains at P0, no difference was
detected at P60 across the analyzed brain regions, except in the striatum, which showed elevated
cholesterol levels (Figure 7A). In contrast, desmosterol levels remained greatly elevated at P60 in
all brain regions, with the most pronounced increase in the striatum (Figure 7A). Surprisingly, the
largest difference in 7-DHC levels was observed at P60, with the most pronounced changes in the
striatum. In addition to brain tissue, several other tissues were analyzed at P60. These include spinal
cord, sciatic and optic nerve (Figure 7B) as well as liver (Figure 7C) and serum (Figure 7D).
Compared to the brain, the serum had the lowest levels of sterols, while the spinal cord, sciatic and

25
optic nerves had a larger amount of sterols. It should be noted that all nervous tissue had much
higher levels of the three sterols than the liver or serum in both WT and Het mice.
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Cholesterol, desmosterol and 7-DHC in liver. While Dhcr24-Het liver has increased desmosterol level, it
does not reach statistical significance (P = 0.0549). D) Sterol levels in serum of Dhcr24-Het mice are not
statistically different from WT livers. n = 4 per group, 2 males and 2 females for each genotype. No sex
differences were observed, so males and females of the same genotype were grouped and analyzed
together. *P < 0.05; ** P < 0.01; ***P < 0.001; ****P < 0.0001.

Elevated desmosterol levels result in complex transcriptional changes
Since sterols are potent regulators of gene expression [90, 91], we screened P0 brain tissue
using specific PCR arrays (Qiagen) to determine if elevated desmosterol changes gene expression.
The pathway-focused panels used in this study include lipoprotein signaling and cholesterol
metabolism, nuclear receptors and coregulators and synaptic plasticity arrays. The screening of
both Dhcr24-KO and Dhcr7-KO brain tissues was done to compare similarities and differences.
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The full list of differentially regulated transcripts and their function is shown in Table 1. Six lipid
transcripts were downregulated and four were upregulated in Dhcr24-KO brain. Among the lipid
transcripts, Dhcr24 was undetectable in Dhcr24-KO brains, and Dhcr7 transcript was undetectable
in Dhcr7-KO brains. Among lipid transcripts with altered expression in Dhcr24-KO brains, three
were also changed in the brains of Dhcr7-KO mice, albeit in the opposing direction. These three
included Srebf1, a transcription factor and two sterol transporters, Abca1 and Abcg1. These findings
are in agreement with elegant studies by Yang et al [92] showing that desmosterol regulates
expression of Abca1 through the activation of LXRs.
Among transcripts encoding nuclear receptors and co-regulators we identified eight
transcripts with downregulated expression in Dhcr24-KO mice and two transcripts altered in
Dhcr7-KO brains (one downregulated and one upregulated). Common between the two disorders
was downregulation of Nr2f2, a transcription factor. While all nuclear receptors were
downregulated in Dhcr24-KO brain, synaptic plasticity transcripts were all upregulated. Of these
four upregulated genes for synaptic plasticity, one encodes a neural cell adhesion molecule, while
the remaining three are transcription factors with expression patterns ranging from ubiquitous to
highly region-specific expression in the brain. To determine if there is a common dysregulated
pathway and visualize the interaction among various transcripts, all genes with altered expression
were uploaded into the STRING database (https://string-db.org/). The visualization of interactions
is shown in Figure 8. This expanded network analysis revealed that these genes had common
interaction partners, suggesting that Dhcr24- and Dhcr7-deficiency might affect the same nuclear
transcriptional network.
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Table 1: Elevated desmosterol changes lipoprotein signaling, cholesterol biosynthesis transcripts,
synaptic plasticity transcripts, nuclear receptors and coregulators. The table shows the gene symbol,
gene name and biological function along with fold regulation and P values. The upregulated transcripts
are shown in blue while downregulated transcripts are shown in red. All statistically significant changes
are shown in red, P < 0.05.

High desmosterol levels alter neuronal outgrowth
Synaptic development is a cholesterol-dependent process and altered sterol composition of
neuronal membranes affects neuronal arborization. For example, in a SLOS mouse model, elevated
7-DHC increases dendritic and axonal length of hippocampal neurons [93] and 7-DHC derived
oxysterols greatly increase neuronal arborization [94]. To test if elevated desmosterol has an effect
on neuronal morphology, we prepared cortical neuronal cultures from embryonic day 15 (E15)
Dhcr24-KO and WT brains. Neurons were cultured for up to six days and their morphology was
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analyzed using the neuron-specific marker microtubule associated protein 2 (MAP2). Imaging and
quantification of total neuronal outgrowth revealed that arborization of Dhcr24-KO neurons was
significantly increased compared to the neuronal outgrowth seen in samples originating from WT
brains (P < 0.0001) (Figure 9A). To corroborate these results, protein was extracted from E18 and
P0 brains, followed by western blotting for MAP2 (Figure 9B-D). This experiment revealed that
MAP2 was also greatly elevated in Dhcr24-KO brains at both E18 and P0, confirming the initially
observed in vitro data.

Figure 8: Interaction network of altered transcripts from PCR arrays. A) Transcripts altered in
Dhcr24-deficient mice. B) Transcripts altered in Dhcr7-deficient mice. The STRING database of known
and predicted biological interactions was used to analyze altered transcripts. Network statistics can be
found in Appendix C.
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Figure 9: MAP2 expression is elevated in Dhcr24-KO brain. A) Total neuronal outgrowth was
compared in WT and KO cultures from E15 cortical neurons. Neuronal cultures in 96-well plates were
stained with MAP2. The total outgrowth was assessed with the ImageXpress Pico Automated Cell Imaging
System using CellReporterXpress software (Molecular Devices, San Jose, CA, USA) and the Neurite
Tracing analysis protocol. Total outgrowth, in µm was normalized to total number of cells. Neuronal
cultures were prepared from 2 WT embryos and 4 KO embryos. For each culture condition, 8 wells with
49 images per well were analyzed at 20X. B) Western blots for MAP2 in whole brain extracts from WT
and Dhcr24-KO pups at P0 and E18, normalized to β-actin and GAPDH, respectively. C,D) Quantification
of band intensities was performed with Azure’s AzureSpot software and graphed in GraphPad Prism 8. *
P < 0.05; **** P < 0.0001.

Amiodarone affects post-lanosterol cholesterol biosynthesis in neuronal and glial
cells
Amiodarone crosses the blood brain barrier and long-term use leads to an increased
incidence in neurological symptoms including tremors, gait ataxia, peripheral neuropathy and
cognitive impairment. Although the mechanism of action in the nervous system is currently
unknown, several reports implicate altered cholesterol biosynthesis [73, 74, 85]. Figure 1B shows
a schematic of post-lanosterol cholesterol biosynthesis including intermediates that were measured
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in the present study. To assess the effects of amiodarone on post-lanosterol synthesis we treated
primary cortical neurons and astrocytes with increasing concentrations of amiodarone and analyzed
levels of sterol intermediates by LC-MS/MS and GC-MS. While cell viability was not affected over
the range of concentrations used, several sterol intermediates were affected by the treatment.
Notably cholesterol content was slightly decreased, with a more pronounced effect in neurons
(Figure 10B) while zymostenol and zymosterol levels are drastically increased compared to DMSO
treatment with the magnitude of increase being much larger in astrocytes (Figure 10A). The
increase in zymostenol and zymosterol suggests that amiodarone inhibits Ebp, the enzyme
responsible for the conversion of zymosterol to 24-dehyrodlathosterol or zymostenol to lathosterol
(Figure 1).

Amiodarone inhibits the sterol biosynthetic enzyme EBP
To confirm that amiodarone treatment produces a similar sterol profile when compared to
EBP inhibition we generated an Ebp-knockdown Neuro2a cell line utilizing shRNA specific to
EBP. These mouse neuroblastoma cells have been used extensively in cholesterol biosynthesis
studies [66-68, 90, 95]. In fact, Dhcr7-deficient Neuro2a cells were key in elucidating the molecular
defects associated with faulty cholesterol synthesis [90, 96]. Using the same methods as previously
mentioned to measure sterol intermediate levels, we compared Ebp-deficient Neuro2a cells with
amiodarone treated Neuro2a cells (Figure 11). While cholesterol levels are modulated in opposite
directions with the two conditions, zymosterol and zymostenol show the same alteration. Note that
while the magnitude of increase in zymosterol for both genetic and chemical inhibition are similar,
the magnitude of change for zymostenol is much greater.
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Figure 11: Comparison of genetic and chemical inhibition of EBP. Cholesterol, zymostenol and
zymosterol levels were measured by GC-MS in Ebp-deficient Neuro2a cultured in defined media for 3
days (A) and Neuro2a treated with 1 µM amiodarone for 3 days (B). *P < 0.05; **P < 0.01; ***P < 0.001.
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Amiodarone users have elevated serum levels of desmosterol, 8-DHC, zymosterol
and zymostenol
Based on the findings from our cell culture experiments we wanted to determine if the
changes in cholesterol biosynthesis were reflected in the serum of human patients taking the
medication. Through the Nebraska Biobank we obtained de-identified serum samples from patients
with amiodarone in their medical records as well as age- and sex-matched samples from control
individuals. Of the 60 samples with amiodarone listed in the medical records we identified 14
samples that contained amiodarone and MDEA in measurable quantities via LC-MS/MS (Figure
12A-C). Of these 14 samples, 9 were given amiodarone orally (Figure 12D, E, gray boxes) while
the remaining 5 received intravenous amiodarone (Figure 12D, E, red boxes). The samples that
came from patients receiving amiodarone orally had higher levels of amiodarone and MDEA in
their plasma on average.
We then analyzed cholesterol, desmosterol and 8-DHC content of the serum by LC-MS/MS
and zymosterol and zymostenol content of the serum by GC-MS of the 14 amiodarone samples
along with the matched controls (Figure 13). As previously reported, desmosterol was significantly
increased in the amiodarone samples. Zymostenol showed a trend towards elevation in response to
treatment. Zymosterol was also increased in the treated samples, although it was only detectable in
6 of 9 oral amiodarone samples and 1 out of 5 intravenous amiodarone samples. Interestingly, 8DHC levels were also increased with amiodarone use, a finding that is consistent with the inhibition
of EBP.
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CHAPTER 4: DISCUSSION
Role of desmosterol in neuronal development
The outcome of our studies can be summarized as follows: A) cholesterol deficiency leads
to early postnatal death or stillborn pups. B) Desmosterol is the second most abundant sterol at P0
during normal development, with a declining trajectory during development in to adulthood. C) In
Dhcr24-KO mice, while desmosterol and 7-DHC are significantly elevated, cholesterol is greatly
decreased. D) Greatly elevated desmosterol in Het brain at P0 continues to stay elevated in the adult
brain. E) Changes in brain sterol composition lead to altered transcriptome response, affecting
synaptic, lipid and nuclear receptor transcripts in a complex fashion. F) Total arborization of
cultured Dhcr24-KO neurons is increased compared to WT neurons.
Studies in the SLOS mouse models were informative and provided a new insight into the
human disorder [97-100], as the sterol biosynthesis pathway is conserved across the two species.
SLOS is the most frequent human disorder caused by mutation in cholesterol biosynthesis enzymes,
and SLOS transgenic mouse models recapitulate molecular and biochemical changes seen in SLOS
patients [17, 42, 72, 101, 102]. Similarly, DHCR24 mutations in desmosterolosis patients share the
same fundamental phenotype with the Dhcr24-KO mice – they have highly elevated desmosterol,
and diminished levels of cholesterol. Thus, the highly conserved cholesterol biosynthesis pathways,
and similarity of biochemical profile between human patients and transgenic mouse models suggest
that the current model is a clinically relevant representation of pathophysiological processes that
take place in the brain of human desmosterolosis patients.
While whole body cholesterol biosynthesis and metabolism have been extensively studied
in the context of energy metabolism and cardiovascular diseases, the origin, role, metabolism and
regulation of the CNS cholesterol pool remains understudied. As shown in this study, desmosterol
is the second most abundant sterol in the brain with rapidly increasing levels prenatally, and steady
levels in adulthood. Thus, this raises the interesting question: does desmosterol have a function of
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its own, and can it influence normal brain function? Jansen et al. proposed that transient
accumulation of desmosterol during early postnatal period may serve to increase the sterol pool in
the brain [103]. This could be accomplished through different mechanisms due to the distinct
chemical properties of desmosterol. Desmosterol has decreased propensity to be esterified as
compared to cholesterol. Additionally, it cannot be hydroxylated to generate 24Shydroxycholesterol and it is capable of activating the LXR-dependent pathway [103]. Based on the
effects of desmosterol on neuronal arborization and synaptic plasticity transcripts that we have
observed, it is conceivable that desmosterol may have additional roles in the regulation of neuronal
differentiation and synaptic remodeling and this should be further investigated.
Our studies and previous findings raise an interesting question. In recessive diseases,
heterozygous parents are typically asymptomatic, with the disease phenotype being expressed only
in the offspring homozygous or compound heterozygous for the mutations. This might not be true
in the case of DHCR24 mutations. Namely, in the three clinical reports of desmosterolosis [20, 22,
26] in addition to description of affected individual, the authors assessed desmosterol levels in
parents (carriers of DHCR24 mutations). All six carriers had elevated plasma desmosterol levels
compared to control samples. In addition, the cultured immortalized lymphocytes obtained from
patient parents showed a 10-fold increase in desmosterol levels compared to control samples. This
finding has potential clinical implications, raising a host of questions. At what level do sterol
intermediates levels become detrimental? How wide is the “normal” range for cholesterol
biosynthesis intermediates? Is the elevated level of desmosterol predisposing, protective or a
modifying factor for another condition?
An interesting and important observation of our study is related to the significantly
increased desmosterol levels of the Dhcr24-Het mice throughout their lifespan. With decreased
DHCR24 activity observed in the Dhcr24-Het mice, we speculate that 7-dehydrodesmosterol (7DHD), the immediate precursor to desmosterol, would also be increased in the brain. This would
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not be surprising and can be extrapolated from the increased 7-DHC levels in the Dhcr24-Het brains
at P0 (Figure 5). The increase in 7-DHC suggests that intermediates upstream to desmosterol on
the pathway would also be affected. Since both 7-DHC and 7-DHD are more prone to oxidation
due to their chemical structure [104, 105], the resulting oxidative products may have cytotoxic
effects in the brain. Thus, in the DHCR24+/- heterozygous human population the elevated
desmosterol and 7-DHD levels have the potential to result in elevated levels of oxysterols and
increased oxidative stress, which might have a long-term effect on overall health status. These
potential oxidative stress effects are likely to be regional and tissue-dependent, as we observed
differences in desmosterol accumulation between the various brain regions. Thus, we propose that
health status of the human heterozygous DHCR24+/- carriers should be carefully assessed, as this
single-copy mutation might affect more than one domain of health and lead to a predisposition to
various disorders in which oxidative stress plays a pathophysiological part.
While desmosterol is greatly elevated in Dhcr24-KO and significantly decreased in Dhcr7KO mice as compared to WT, 7-DHC was increased in both of these two mouse models, and both
disorders are characterized by markedly decreased cholesterol levels in the brain. Thus, it is perhaps
not surprising that the molecular and microanatomical changes also show some similarities between
Dhcr24-KO and Dhcr7-KO mice. Namely, the affected gene expression, while not identical across
the two mouse models, impact the same transcriptional networks, and increased neuronal
arborization is a feature of both models. Untangling the precise origin of all these changes is
challenging and we propose that the primary driver of the majority of common changes is lack of
cholesterol, while the Dhcr24-KO specific changes are due to elevated desmosterol levels.
However, we acknowledge that increased neural arborization can be potentially a result of
increased 7-DHC observed in both models, and might be due to the previously reported toxic effect
of 7-DHC derived oxysterols [91, 96].
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In conclusion, desmosterol is an abundant, temporally regulated precursor of cholesterol in
brain cells, with putative physiological function. Its disturbances might be a significant contributor
to disease states, and this should be further investigated.

Amiodarone affects cholesterol biosynthesis
Our results can be summarized as follows: (A) Amiodarone inhibits Ebp in astrocytes and
neurons leading to dose-dependent increases in zymosterol and zymostenol. (B) Genetic inhibition
and chemical inhibition of Ebp yield similar results in Neuro2a cells. (C) Amiodarone and MDEA
are present in measurable quantities in patient serum samples. (D) Patient samples with detectable
levels of amiodarone or MDEA have elevated levels of desmosterol, 8-DHC and zymosterol as
well as a slight increase in zymostenol.
The biochemical findings from cell culture systems and patient serum implicate two
enzymes that are subject to inhibition by amiodarone: Dhcr24 and Ebp. The strongest effect in
neuronal cells is the inhibition of Ebp. Ebp is responsible for the conversion of zymosterol to 24dehyrodlathosterol and zymostenol to lathosterol, as well as the isomerization of 7-DHC to 8-DHC,
thus explaining the elevation of zymostenol and zymosterol in the neuronal and astrocytic cultures
in response to amiodarone treatment. The elegant studies by Moebius and colleagues [106-109]
analyzed the pharmacological properties of EBP. In their work they found that, in vitro, EBP can
bind structurally diverse drugs with high affinity, including amiodarone.
Interestingly, the increase in zymostenol due to amiodarone treatment in astrocytes is
roughly 5 times higher than in neurons. Additionally, the magnitude of change in zymosterol is
about twice as large in astrocytes as well, which may indicate that they are more susceptible to
chemical alterations in cholesterol biosynthesis. Overall the profile in astrocytes and neurons was
very similar to what was observed in Ebp-deficient cells.
Amiodarone measurements in the clinical population are in agreement with the study in
cell culture system, suggesting an effect on more than one enzyme. An interesting trend appeared
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in the desmosterol, zymostenol and zymosterol results when the administration method was taken
in to consideration. Intravenous administration (Figure 13, red boxes) tended to cluster with lower
levels of the intermediates while oral administration in the form of a tablet (Figure 13, gray boxes)
clustered at the higher end of the mentioned sterols. Interestingly, only 1 of the 5 samples with
intravenous administration had detectable levels of zymosterol whereas it was detectable in 6 of 9
samples that received oral administration. In fact, when comparing only samples that had a history
of oral amiodarone usage, the elevation in zymostenol becomes statistically significant, as well
increasing the mean desmosterol levels (Figure 14). It is important to take into consideration that
amiodarone treatment can range from weeks to years [84]. Unfortunately, the length of treatment
was not available for these samples, but intravenous administration is primarily used for short-term
management of serious arrhythmias so it follows that those samples would have lesser effects
reflected in their serum sterol levels. Thus, the alteration in sterol levels is apparently timedependent which is consistent with the major risk factor for developing toxic neurological effects
being treatment duration.
Amiodarone has a very narrow therapeutic range (1.0-2.5 µg/mL) [110] and the toxicity is
linked to concentrations above 2.5 µg/mL [111]. However, the highest level of amiodarone in the
patient samples we analyzed was 0.176 µg/mL, while the remainder of the samples had a range of
0.0013 – 0.0184 µg/mL (median 0.0061 µg/mL) (Figure 12). Despite the samples analyzed in the
present study being much below the reported therapeutic range, let alone near the toxicity threshold,
observable changes in cholesterol intermediates are still present and significant. These changes
would be much more pronounced in amiodarone users with high plasma concentration of
amiodarone. Furthermore, due to the lipophilic nature of amiodarone and MDEA it is likely that
the tissue specific concentrations of these drugs is even higher than what is observed in the serum
and thus the effects on cholesterol biosynthesis may be even more pronounced in tissue due to the
local concentration of the drug.
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Figure 14: Sterol measurements in human serum samples that received oral administration of
amiodarone. Serum samples that were confirmed to contain amiodarone and/or MDEA were analyzed by
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While amiodarone has been beneficial in the treatment of life-threatening arrhythmias, it
has many side effects. At the cellular/molecular levels, since amiodarone is lipophilic, it easily
accumulates in cells where it can cause mitochondrial damage and structural and functional
disturbances in the late endosomes and lysosomes. This may lead to a so-called ‘lipid traffic jam’
and in the liver, amiodarone use can lead to nonalcoholic steatohepatitis. Desmosterol levels in the
liver and serum correlate with the severity of steatosis and inflammation [112]. The number of
amiodarone prescriptions in the USA for 2006-2016 was 37,806,878 with a yearly average of
3,436,989 (median 3,404,961) [79]. Additionally, amiodarone is considered a category D drug by
the FDA, meaning that there is positive evidence of human fetal risk and careful consideration is
critical for the use of this drug during pregnancy. Therefore, careful clinical evaluation and
monitoring of the adverse side effects is warranted in long-term amiodarone use.
This study provides insight into the consequences of amiodarone’s inhibition of cholesterol
synthesis and warrants careful monitoring of blood biochemistry in amiodarone users. It is
imperative that this monitoring goes beyond the standard cholesterol measurements as cholesterol
levels on their own may not indicate a problem as seen in Figure 13 and Figure 14, as there was
no observable difference in cholesterol between the two groups but the levels of the intermediates
differed greatly. Additionally, the screening of novel compounds with structures similar to
amiodarone should include testing for the inhibition of the EBP and other sterol enzymes to avoid
unintended interference with cholesterol biosynthesis.
Numerous studies have attempted to determine if plasma lipid measurements or
pharmaceutical manipulations affect cognitive functions and brain neurochemistry [113, 114].
While there is no definitive answer when analyzing cholesterol levels in human serum samples,
based on our limited studies in transgenic mouse models of cholesterol disorders, it is clear that
serum sterol levels reflect cholesterol biosynthesis in brain and other tissues (Figure 7). However,
the magnitude of change is much more pronounced in tissues compared to serum and the brain has

43
much larger change than other organs. Similarly, the levels of intermediates are much more
representative of the defect in cholesterol synthesis than the level of cholesterol due in part to the
effect of diet on cholesterol levels.

Conclusions
The characterization of desmosterolosis revealed a number of commonalities with what
has been previously observed in various SLOS models. These include a drastic reduction in the
amount of cholesterol present in the brain, prenatal lethality in knockouts, a marked alteration in
sterol intermediate levels which result in alterations in gene transcription (Table 1) as well as the
phenotype of primary neurons. It is important to keep in mind that these intermediates have other
biological roles in addition to simply being just stepping stones on the way to cholesterol. However,
a buildup of 7-DHC and desmosterol are not equal – due to the highly reactive nature of 7-DHC
and its propensity to form oxidized sterols, known as oxysterols, 7-DHC buildup is particularly
problematic as it has been shown that high levels of oxysterols are toxic [91]. It is important to
consider the role that a desmosterol precursor, 7-dehydrodesmosterol, has been calculated to be
equally as prone to oxidation as 7-DHC [104], however due to the reactive nature and relative
scarcity of this sterol in tissues it was not measured in the present study.
In addition to genetic elevation of cholesterol intermediates there are significant number of
medications that have elevation of cholesterol intermediates as a side effect. Previous screening
studies estimate about 5% of compounds out of ~3,000 analyzed have unintended effects on
cholesterol biosynthesis. It is obvious that more potent inhibitors of sterol enzymes are problematic,
such was the case in the removal of triparanol from the market. Many of the side effects of
triparanol that lead to its withdrawal from the market are analogous to what is observed in the side
effects of amiodarone use. For example, triparanol induced cataracts whereas corneal microdeposits
are observed in “virtually all patients who receive amiodarone for more than 6 months” [115].
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The major focus in the present study was on the neurodevelopmental consequences of
perturbed cholesterol biosynthesis. Altered levels of cholesterol and its replacement with
intermediates has devastating effects on the development of the nervous system. Similarly the use
of medications that disrupt cholesterol synthesis during pregnancy have significant negative effects
on the developing fetus as seen in the case of amiodarone use during pregnancy [76] in addition to
the well-described teratogenic effects of other cholesterol disrupting medications [63]. These
disruptions are much more serious for developing neurons as their rate of cholesterol biosynthesis
is much higher than that of mature neurons [9] so they will more quickly feel the effects of the
disruption, which then translates to neurological and developmental issues in humans.
Future studies should focus on further exploring the extent to which unintended
perturbations of cholesterol biosynthesis may contribute to side effects of commonly prescribed
medications. Utilizing different models to understand the implications of these disruptions is vital
in understanding the biological consequences that arise from disrupting cholesterol biosynthesis.
Despite the fact that desmosterolosis is an incredibly rare disease, studying the etiology and
pathophysiology of the disease illustrates the role certain biomolecules have in normal
development. Likewise, understanding how different medications interact with this pathway may
be informed by studying genetic disorders in the pathway and how they manifest. Furthermore, in
the age of personalized medicine, understanding the full array of effects of a given medication is
especially important when certain medications can interact and have devastating outcomes with
different genotypes. For example, approximately 1.5% of the population carries a mutation in the
Dhcr7 gene that encodes 7-dehydrocholesterol reductase, the enzyme in which dysfunction leads
to SLOS. These mutations have been shown to interact with either aripiprazole [70] or cariprazine
[116], two commonly prescribed antipsychotics known to inhibit DHCR7, which can lead to
devastating neurodevelopmental outcome in the event that a carrier of one of these mutations takes
these drugs during pregnancy. Therefore, further study of disruptions in cholesterol biosynthesis
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will not only help inform clinicians of potentially devastating side effects, but also expand on the
current knowledge of a pathway that, while essential for life, is not fully understood.
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APPENDIX A: STEROL INFORMATION
Table 2: Common names of sterols used with detailed information.

APPENDIX B: STEROL BIOSYNTHESIS DISORDERS
Table 3: Comparison of cholesterol synthesis disorders.

Nomenclature Committee of the International Union of Biochemistry and Molecular Biology
(IUBMB) describes each type of characterized enzyme for which an EC (Enzyme Commission)
number has been provided.
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APPENDIX C: NETWORK STATISTICS OF ALTERED
TRANSCRIPTS FROM PCR ARRAYS

Figure 15: Network statistics of altered transcripts from PCR arrays. A) Transcripts altered in
Dhcr24-deficient mice. B) Transcripts altered in Dhcr7-deficient mice. The STRING database of
known and predicted biological interactions was used to analyze altered transcripts. Network
interactions are shown in Figure 8.
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APPENDIX D: ZYMOSTEROL AND ZYMOSTENOL GC-MS
CHROMATOGRAMS AND MASS SPECTRA
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Figure 16: GC-MS analysis of zymosterol. A) Chromatogram (top) and mass spectrum (bottom) for pure
zymosterol purchased from Kerafast. B) Typical chromatogram and mass spectrum obtained from control
treated astrocytes. C) Typical chromatogram and mass spectrum obtained from astrocytes treated with 1 µM
amiodarone for 5 days. Note the increase in peak size in C as well as the increase in the m/z 456 ion upon
treatment with amiodarone.
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Figure 17: GC-MS analysis of zymostenol. A) Chromatogram (top) and mass spectrum (bottom) for pure
zymostenol purchased from Kerafast. B) Typical chromatogram and mass spectrum obtained from control
treated astrocytes. C) Typical chromatogram and mass spectrum obtained from astrocytes treated with 1 µM
amiodarone for 5 days. Note the increase in peak size in C as well as the increase in the m/z 458 ion upon
treatment with amiodarone.
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APPENDIX E: REAGENT TABLE

50

BIBLIOGRAPHY
1.

Jurevics, H. and P. Morell, Cholesterol for synthesis of myelin is made locally, not imported
into brain. J Neurochem, 1995. 64(2): p. 895-901.

2.

Lutjohann, D. and K. von Bergmann, 24S-hydroxycholesterol: a marker of brain
cholesterol metabolism. Pharmacopsychiatry, 2003. 36 Suppl 2: p. S102-6.

3.

Pfrieger, F.W., Outsourcing in the brain: do neurons depend on cholesterol delivery by
astrocytes? Bioessays, 2003. 25(1): p. 72-8.

4.

Strandberg, T.E. and R.S. Tilvis, Physiological and pharmacological regulation of small
intestinal cholesterol synthesis. Gen Pharmacol, 1988. 19(3): p. 321-9.

5.

Shepherd, J., Lipoprotein metabolism. An overview. Drugs, 1994. 47 Suppl 2: p. 1-10.

6.

Dietschy, J.M. and S.D. Turley, Cholesterol metabolism in the brain. Curr Opin Lipidol,
2001. 12(2): p. 105-12.

7.

Tint, G.S., et al., Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz
syndrome. N Engl J Med, 1994. 330(2): p. 107-13.

8.

Tint, G.S., et al., Markedly increased tissue concentrations of 7-dehydrocholesterol
combined with low levels of cholesterol are characteristic of the Smith-Lemli-Opitz
syndrome. J Lipid Res, 1995. 36(1): p. 89-95.

9.

Dietschy, J.M. and S.D. Turley, Thematic review series: brain Lipids. Cholesterol
metabolism in the central nervous system during early development and in the mature
animal. J Lipid Res, 2004. 45(8): p. 1375-97.

10.

Herman, G.E., Disorders of cholesterol biosynthesis: prototypic metabolic malformation
syndromes. Hum Mol Genet, 2003. 12 Spec No 1: p. R75-88.

11.

Nicholas, H.J. and B.E. Thomas, Cholesterol metabolism and the blood-brain barrier: an
experimental study with 2-C14-sodium acetate. Brain, 1961. 84: p. 320-8.

12.

Korade, Z., et al., Expression and p75 neurotrophin receptor dependence of cholesterol
synthetic enzymes in adult mouse brain. Neurobiol Aging, 2007. 28(10): p. 1522-31.

13.

Korade, Z. and A.K. Kenworthy, Lipid rafts, cholesterol, and the brain.
Neuropharmacology, 2008. 55(8): p. 1265-73.

14.

Cooper, M.K., et al., A defective response to Hedgehog signaling in disorders of
cholesterol biosynthesis. Nat Genet, 2003. 33(4): p. 508-13.

15.

Huang, T.L. and J.F. Chen, Cholesterol and lipids in depression: stress, hypothalamopituitary-adrenocortical axis, and inflammation/immunity. Adv Clin Chem, 2005. 39: p.
81-105.

16.

You, H., et al., The relationship between statins and depression: a review of the literature.
Expert Opin Pharmacother, 2013. 14(11): p. 1467-76.

17.

Porter, F.D., Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur
J Hum Genet, 2008. 16(5): p. 535-41.

18.

Steiner, R.D., et al., Sterol balance in the Smith-Lemli-Opitz syndrome. Reduction in whole
body cholesterol synthesis and normal bile acid production. J Lipid Res, 2000. 41(9): p.
1437-47.

51
19.

Allen, L.B., et al., Desmosterolosis and desmosterol homeostasis in the developing mouse
brain. J Inherit Metab Dis, 2019. 42(5): p. 934-943.

20.

Andersson, H.C., L. Kratz, and R. Kelley, Desmosterolosis presenting with multiple
congenital anomalies and profound developmental delay. Am J Med Genet, 2002. 113(4):
p. 315-9.

21.

Dias, C., et al., Desmosterolosis: an illustration of diagnostic ambiguity of cholesterol
synthesis disorders. Orphanet J Rare Dis, 2014. 9: p. 94.

22.

FitzPatrick, D.R., et al., Clinical phenotype of desmosterolosis. Am J Med Genet, 1998.
75(2): p. 145-52.

23.

Rohanizadegan, M. and S. Sacharow, Desmosterolosis presenting with multiple congenital
anomalies. Eur J Med Genet, 2018. 61(3): p. 152-156.

24.

Schaaf, C.P., et al., Desmosterolosis-phenotypic and molecular characterization of a third
case and review of the literature. Am J Med Genet A, 2011. 155A(7): p. 1597-604.

25.

Waterham, H.R., et al., Mutations in the 3beta-hydroxysterol Delta24-reductase gene
cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J
Hum Genet, 2001. 69(4): p. 685-94.

26.

Zolotushko, J., et al., The desmosterolosis phenotype: spasticity, microcephaly and
micrognathia with agenesis of corpus callosum and loss of white matter. Eur J Hum Genet,
2011. 19(9): p. 942-6.

27.

Rosenbaum, A.I. and F.R. Maxfield, Niemann-Pick type C disease: molecular mechanisms
and potential therapeutic approaches. J Neurochem, 2011. 116(5): p. 789-95.

28.

Kolsch, H., et al., CYP46A1 variants influence Alzheimer's disease risk and brain
cholesterol metabolism. Eur Psychiatry, 2009. 24(3): p. 183-90.

29.

Leoni, V. and C. Caccia, Study of cholesterol metabolism in Huntington's disease. Biochem
Biophys Res Commun, 2014. 446(3): p. 697-701.

30.

Leoni, V. and C. Caccia, The impairment of cholesterol metabolism in Huntington disease.
Biochim Biophys Acta, 2015. 1851(8): p. 1095-105.

31.

Martin, M.G., F. Pfrieger, and C.G. Dotti, Cholesterol in brain disease: sometimes
determinant and frequently implicated. EMBO Rep, 2014. 15(10): p. 1036-52.

32.

Sparks, D.L., Cholesterol metabolism and brain amyloidosis: evidence for a role of copper
in the clearance of Abeta through the liver. Curr Alzheimer Res, 2007. 4(2): p. 165-9.

33.

Bianconi, S.E., et al., Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of
Smith-Lemli-Opitz Syndrome. Expert Opin Orphan Drugs, 2015. 3(3): p. 267-280.

34.

Chang, S., et al., Elevated Autophagy and Mitochondrial Dysfunction in the Smith-LemliOpitz Syndrome. Mol Genet Metab Rep, 2014. 1: p. 431-442.

35.

Herman, G.E. and L. Kratz, Disorders of sterol synthesis: beyond Smith-Lemli-Opitz
syndrome. Am J Med Genet C Semin Med Genet, 2012. 160C(4): p. 301-21.

36.

Kelley, R.I., Inborn errors of cholesterol biosynthesis. Adv Pediatr, 2000. 47: p. 1-53.

37.

Nwokoro, N.A., C.A. Wassif, and F.D. Porter, Genetic disorders of cholesterol
biosynthesis in mice and humans. Mol Genet Metab, 2001. 74(1-2): p. 105-19.

38.

Moebius, F.F., et al., Molecular cloning and expression of the human delta7-sterol
reductase. Proc Natl Acad Sci U S A, 1998. 95(4): p. 1899-902.

52
39.

Battaile, K.P., et al., Carrier frequency of the common mutation IVS8-1G>C in DHCR7
and estimate of the expected incidence of Smith-Lemli-Opitz syndrome. Mol Genet Metab,
2001. 72(1): p. 67-71.

40.

Cross, J.L., et al., Determination of the allelic frequency in Smith-Lemli-Opitz syndrome
by analysis of massively parallel sequencing data sets. Clin Genet, 2015. 87(6): p. 570-5.

41.

Ginat, S., et al., Lowered DHCR7 activity measured by ergosterol conversion in multiple
cell types in Smith-Lemli-Opitz syndrome. Mol Genet Metab, 2004. 83(1-2): p. 175-83.

42.

Porter, F.D., Malformation syndromes due to inborn errors of cholesterol synthesis. J Clin
Invest, 2002. 110(6): p. 715-24.

43.

Boland, M.R. and N.P. Tatonetti, Investigation of 7-dehydrocholesterol reductase pathway
to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.
Pharmacogenomics J, 2016. 16(5): p. 411-29.

44.

Sikora, D.M., et al., The near universal presence of autism spectrum disorders in children
with Smith-Lemli-Opitz syndrome. Am J Med Genet A, 2006. 140(14): p. 1511-8.

45.

Tierney, E., et al., Abnormalities of cholesterol metabolism in autism spectrum disorders.
Am J Med Genet B Neuropsychiatr Genet, 2006. 141B(6): p. 666-8.

46.

Anderson, R., et al., Lathosterolosis: A Relatively Mild Case with Cataracts and Learning
Difficulties. JIMD Rep, 2019. 44: p. 79-84.

47.

Derry, J.M., et al., Mutations in a delta 8-delta 7 sterol isomerase in the tattered mouse
and X-linked dominant chondrodysplasia punctata. jderry@immunex.com. Nat Genet,
1999. 22(3): p. 286-90.

48.

Kelley, R.I., et al., Abnormal sterol metabolism in patients with Conradi-HunermannHapple syndrome and sporadic lethal chondrodysplasia punctata. Am J Med Genet, 1999.
83(3): p. 213-9.

49.

Uwechue, I.C., et al., The mouse X-linked developmental mutant, tattered, lies between
DXMit55 and Xkh and is associated with hyperkeratinization. Genomics, 1996. 37(2): p.
238-41.

50.

Arnold, A.W., et al., Conradi-Hunermann-Happle syndrome in males vs. MEND syndrome
(male EBP disorder with neurological defects). Br J Dermatol, 2012. 166(6): p. 1309-13.

51.

Aughton, D.J., et al., X-linked dominant chondrodysplasia punctata (CDPX2) caused by
single gene mosaicism in a male. Am J Med Genet A, 2003. 116A(3): p. 255-60.

52.

Sutphen, R., et al., XXY male with X-linked dominant chondrodysplasia punctata (Happle
syndrome). Am J Med Genet, 1995. 57(3): p. 489-92.

53.

Wechsler, A., et al., Generation of viable cholesterol-free mice. Science, 2003. 302(5653):
p. 2087.

54.

Ohyama, Y., et al., Studies on the transcriptional regulation of cholesterol 24-hydroxylase
(CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem, 2006.
281(7): p. 3810-20.

55.

Heverin, M., et al., Studies on the cholesterol-free mouse: strong activation of LXRregulated hepatic genes when replacing cholesterol with desmosterol. Arterioscler Thromb
Vasc Biol, 2007. 27(10): p. 2191-7.

53
56.

Lu, X., et al., DHCR24-knockout embryonic fibroblasts are susceptible to serum
withdrawal-induced apoptosis because of dysfunction of caveolae and insulin-Akt-Bad
signaling. Endocrinology, 2006. 147(6): p. 3123-32.

57.

Mirza, R., et al., Increased expression of aquaporin-3 in the epidermis of DHCR24
knockout mice. Br J Dermatol, 2008. 158(4): p. 679-84.

58.

Mirza, R., et al., DHCR24 gene knockout mice demonstrate lethal dermopathy with
differentiation and maturation defects in the epidermis. J Invest Dermatol, 2006. 126(3):
p. 638-47.

59.

Mirza, R., et al., Requirement of DHCR24 for postnatal development of epidermis and hair
follicles in mice. Am J Dermatopathol, 2009. 31(5): p. 446-52.

60.

Kuehnle, K., et al., Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses
to oxidative stress. Mol Cell Biol, 2008. 28(2): p. 539-50.

61.

Steinberg, D., The cholesterol wars : the skeptics vs. the preponderance of evidence. 1st
ed. 2007, San Diego, Calif.: Academic Press. xx, 227 p., 3 p. of plates.

62.

Kirby, T.J., Cataracts produced by triparanol. (MER-29). Trans Am Ophthalmol Soc,
1967. 65: p. 494-543.

63.

Roux, C., C. Horvath, and R. Dupuis, Teratogenic action and embryo lethality of AY
9944R. Prevention by a hypercholesterolemia-provoking diet. Teratology, 1979. 19(1): p.
35-8.

64.

Correa-Cerro, L.S., et al., Development and characterization of a hypomorphic SmithLemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. Hum Mol Genet,
2006. 15(6): p. 839-51.

65.

Xu, L., et al., 7-Dehydrocholesterol-derived oxysterols and retinal degeneration in a rat
model of Smith-Lemli-Opitz syndrome. Biochim Biophys Acta, 2012. 1821(6): p. 877-83.

66.

Kim, H.Y., et al., Inhibitors of 7-Dehydrocholesterol Reductase: Screening of a Collection
of Pharmacologically Active Compounds in Neuro2a Cells. Chem Res Toxicol, 2016.
29(5): p. 892-900.

67.

Korade, Z., et al., The Effect of Small Molecules on Sterol Homeostasis: Measuring 7Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts. J Med
Chem, 2016. 59(3): p. 1102-15.

68.

Wages, P.A., et al., Identification and characterization of prescription drugs that change
levels of 7-dehydrocholesterol and desmosterol. J Lipid Res, 2018. 59(10): p. 1916-1926.

69.

Korade, Z., et al., Effect of psychotropic drug treatment on sterol metabolism. Schizophr
Res, 2017. 187: p. 74-81.

70.

Genaro-Mattos, T.C., et al., Maternal aripiprazole exposure interacts with 7dehydrocholesterol reductase mutations and alters embryonic neurodevelopment. Mol
Psychiatry, 2019. 24(4): p. 491-500.

71.

Bulletins--Obstetrics, A.C.o.P., ACOG Practice Bulletin: Clinical management guidelines
for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number
87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Obstet Gynecol, 2008. 111(4): p. 1001-20.

72.

Porter, F.D. and G.E. Herman, Malformation syndromes caused by disorders of cholesterol
synthesis. J Lipid Res, 2011. 52(1): p. 6-34.

54
73.

Pollak, P.T., A.D. Sharma, and S.G. Carruthers, Elevation of serum total cholesterol and
triglyceride levels during amiodarone therapy. Am J Cardiol, 1988. 62(9): p. 562-5.

74.

Pollak, P.T. and M.H. Tan, Elevation of high-density lipoprotein cholesterol in humans
during long-term therapy with amiodarone. Am J Cardiol, 1999. 83(2): p. 296-300, A7.

75.

Simonen, P., et al., Desmosterol accumulation in users of amiodarone. J Intern Med, 2018.
283(1): p. 93-101.

76.

Mikovic, Z., et al., Developmental delay associated with normal thyroidal function and
long-term amiodarone therapy during fetal and neonatal life. Biomed Pharmacother, 2010.
64(6): p. 396-8.

77.

Amiodarone Hydrochloride [package insert]. Philadelphia, P., Wyeth Pharmaceuticals Inc.
2004.

78.

Humphries, E.S. and C. Dart, Neuronal and Cardiovascular Potassium Channels as
Therapeutic Drug Targets: Promise and Pitfalls. J Biomol Screen, 2015. 20(9): p. 105573.

79.

Kane, S. Amiodarone Hydrochloride. November 24, 2018 [cited 2019 October 24]; Available
from: https://clincalc.com/DrugStats/Drugs/AmiodaroneHydrochloride.

80.

World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva:
World Health Organization 2019, (Licence: CC BY-NC-SA 3.0 IGO.).

81.

January, C.T., et al., 2014 AHA/ACC/HRS guideline for the management of patients with
atrial fibrillation: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll
Cardiol, 2014. 64(21): p. e1-76.

82.

Fox, L.M., The Science and Practice of Pharmacy, 21st Edition. Am J Pharm Educ, 2006.
70(3).

83.

Pollak, P.T., A.D. Sharma, and S.G. Carruthers, Correlation of amiodarone dosage, heart
rate, QT interval and corneal microdeposits with serum amiodarone and
desethylamiodarone concentrations. Am J Cardiol, 1989. 64(18): p. 1138-43.

84.

Orr, C.F. and J.E. Ahlskog, Frequency, characteristics, and risk factors for amiodarone
neurotoxicity. Arch Neurol, 2009. 66(7): p. 865-9.

85.

Mesens, N., et al., Phospholipidosis in rats treated with amiodarone: serum biochemistry
and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the
subsequent rise of the biomarker BMP. Toxicol Pathol, 2012. 40(3): p. 491-503.

86.

Levitan, I., et al., Cholesterol and ion channels. Subcell Biochem, 2010. 51: p. 509-49.

87.

Jirsova, K., et al., Cold jet: a method to obtain pure Schwann cell cultures without the need
for cytotoxic, apoptosis-inducing drug treatment. J Neurosci Methods, 1997. 78(1-2): p.
133-7.

88.

Tint, G.S., et al., The use of the Dhcr7 knockout mouse to accurately determine the origin
of fetal sterols. J Lipid Res, 2006. 47(7): p. 1535-41.

89.

Lamberson, C.R., et al., Unusual kinetic isotope effects of deuterium reinforced
polyunsaturated fatty acids in tocopherol-mediated free radical chain oxidations. J Am
Chem Soc, 2014. 136(3): p. 838-41.

90.

Korade, Z., A.K. Kenworthy, and K. Mirnics, Molecular consequences of altered neuronal
cholesterol biosynthesis. J Neurosci Res, 2009. 87(4): p. 866-75.

55
91.

Korade, Z., et al., Biological activities of 7-dehydrocholesterol-derived oxysterols:
implications for Smith-Lemli-Opitz syndrome. J Lipid Res, 2010. 51(11): p. 3259-69.

92.

Yang, C., et al., Sterol intermediates from cholesterol biosynthetic pathway as liver X
receptor ligands. J Biol Chem, 2006. 281(38): p. 27816-26.

93.

Jiang, X.S., et al., Quantitative proteomics analysis of inborn errors of cholesterol
synthesis: identification of altered metabolic pathways in DHCR7 and SC5D deficiency.
Mol Cell Proteomics, 2010. 9(7): p. 1461-75.

94.

Xu, L., et al., DHCEO accumulation is a critical mediator of pathophysiology in a SmithLemli-Opitz syndrome model. Neurobiol Dis, 2012. 45(3): p. 923-9.

95.

Korade, Z., et al., NRIF is a regulator of neuronal cholesterol biosynthesis genes. J Mol
Neurosci, 2009. 38(2): p. 152-8.

96.

Xu, L., et al., An oxysterol biomarker for 7-dehydrocholesterol oxidation in cell/mouse
models for Smith-Lemli-Opitz syndrome. J Lipid Res, 2011. 52(6): p. 1222-33.

97.

Korade, Z., et al., Antioxidant supplementation ameliorates molecular deficits in SmithLemli-Opitz syndrome. Biol Psychiatry, 2014. 75(3): p. 215-22.

98.

Sharif, N.F., et al., Oxidative stress, serotonergic changes and decreased ultrasonic
vocalizations in a mouse model of Smith-Lemli-Opitz syndrome. Genes Brain Behav, 2017.
16(6): p. 619-626.

99.

Sparks, S.E., et al., Decreased cerebral spinal fluid neurotransmitter levels in Smith-LemliOpitz syndrome. J Inherit Metab Dis, 2014. 37(3): p. 415-20.

100.

Waage-Baudet, H., et al., Abnormal serotonergic development in a mouse model for the
Smith-Lemli-Opitz syndrome: implications for autism. Int J Dev Neurosci, 2003. 21(8): p.
451-9.

101.

Porter, F.D., RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental
retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab,
2000. 71(1-2): p. 163-74.

102.

Porter, F.D., Human malformation syndromes due to inborn errors of cholesterol synthesis.
Curr Opin Pediatr, 2003. 15(6): p. 607-13.

103.

Jansen, M., et al., What dictates the accumulation of desmosterol in the developing brain?
FASEB J, 2013. 27(3): p. 865-70.

104.

Lamberson, C.R., et al., Propagation rate constants for the peroxidation of sterols on the
biosynthetic pathway to cholesterol. Chem Phys Lipids, 2017. 207(Pt B): p. 51-58.

105.

Yin, H., L. Xu, and N.A. Porter, Free radical lipid peroxidation: mechanisms and analysis.
Chem Rev, 2011. 111(10): p. 5944-72.

106.

Moebius, F.F., et al., Yeast sterol C8-C7 isomerase: identification and characterization of
a high-affinity binding site for enzyme inhibitors. Biochemistry, 1996. 35(51): p. 16871-8.

107.

Moebius, F.F., et al., Cloning of an emopamil-binding protein (EBP)-like protein that lacks
sterol delta8-delta7 isomerase activity. Biochem J, 2003. 374(Pt 1): p. 229-37.

108.

Moebius, F.F., et al., Pharmacological analysis of sterol delta8-delta7 isomerase proteins
with [3H]ifenprodil. Mol Pharmacol, 1998. 54(3): p. 591-8.

56
109.

Moebius, F.F., et al., High affinity of sigma 1-binding sites for sterol isomerization
inhibitors: evidence for a pharmacological relationship with the yeast sterol C8-C7
isomerase. Br J Pharmacol, 1997. 121(1): p. 1-6.

110.

Rotmensch, H.H., et al., Steady-state serum amiodarone concentrations: relationships with
antiarrhythmic efficacy and toxicity. Ann Intern Med, 1984. 101(4): p. 462-9.

111.

Haffajee, C.I., Clinical pharmacokinetics of amiodarone. Clin Cardiol, 1987. 10(7 Suppl
1): p. I6-9.

112.

Simonen, M., et al., Desmosterol in human nonalcoholic steatohepatitis. Hepatology,
2013. 58(3): p. 976-82.

113.

Cenik, B., et al., Plasma sterols and depressive symptom severity in a population-based
cohort. PLoS One, 2017. 12(9): p. e0184382.

114.

Wellington, C.L. and R. Frikke-Schmidt, Relation between plasma and brain lipids. Curr
Opin Lipidol, 2016. 27(3): p. 225-32.

115.

Dovie, J.M. and A.S. Gurwood, Acute onset of halos and glare: bilateral corneal epithelial
edema with cystic eruptions--atypical presentation of amiodarone keratopathy. Optometry,
2006. 77(2): p. 76-81.

116.

Genaro-Mattos, T.C., et al., Dichlorophenyl piperazines, including a recently-approved
atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol
biosynthesis. Toxicol Appl Pharmacol, 2018. 349: p. 21-28.

